Exploiting a cross-reactive epitope in Plasmodium vivax PvDBP to develop a vaccine against falciparum placental malaria

利用间日疟原虫 PvDBP 中的交叉反应表位开发针对恶性胎盘疟疾的疫苗

• 批准号: 408726
• 负责人: Yanow Stephanie K
• 金额: $ 57.96万
• 依托单位: University of Alberta
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2019
• 资助国家: 加拿大
• 起止时间: 2019-09-01 至 2024-09-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=408726&lang=en
• 关键词: Antigens; Falciparum; Immunity; Immunogenicity; Malaria; Placenta; Pre-Clinical; Pregnancy; Vaccines; Vivax

Over 125 million pregnancies annually are at risk of complications from malaria that threaten the life of the mother and fetus. A vaccine to protect pregnant women from malaria is urgently needed and can save an estimated 10,000 mothers and 200,000 newbor

每年有超过1.25亿孕妇面临疟疾并发症的风险，威胁母亲和胎儿的生命。迫切需要一种保护孕妇免受疟疾侵害的疫苗，估计可以挽救10，000名母亲和200，000名新生儿